Reviparin: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
No edit summary |
||
| Line 24: | Line 24: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
'''Reviparin''' is an antithrombotic in the [[heparin]] group. | '''Reviparin''' is an antithrombotic in the [[heparin]] group. | ||
==External | ==External Links== | ||
* {{MeshName|reviparin}} | * {{MeshName|reviparin}} | ||
* {{cite journal |author=Yusuf S, Mehta SR, Xie C, ''et al'' |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427-35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427}} | * {{cite journal |author=Yusuf S, Mehta SR, Xie C, ''et al'' |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427-35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427}} | ||
==References== | |||
{{reflist|2}} | |||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category:Drugs]] | [[Category:Drug]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Anticoagulants]] | |||
Revision as of 00:50, 26 July 2014
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Reviparin |
|
Articles |
|---|
|
Most recent articles on Reviparin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Reviparin at Clinical Trials.gov Clinical Trials on Reviparin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Reviparin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Reviparin Discussion groups on Reviparin Directions to Hospitals Treating Reviparin Risk calculators and risk factors for Reviparin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Reviparin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Reviparin is an antithrombotic in the heparin group.
External Links
- reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
- Yusuf S, Mehta SR, Xie C; et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Drug
- Cardiovascular Drugs
- Anticoagulants